Kuwait Medical Electronic Library

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Emek Kocatürk 1, Andaç Salman 2, Ivan Cherrez-Ojeda 3, Paulo Ricardo Criado 4 5 6, Jonny Peter 7, Elif Comert-Ozer 2, Mohamed Abuzakouk 8, Rosana Câmara Agondi 9, Mona Al-Ahmad 10, Sabine Altrichter 11, Rand Arnaout 12, Luisa Karla Arruda 13, Riccardo Asero 14, Andrea Bauer 15, Moshe Ben-Shoshan 16, Jonathan A Bernstein 17, Mojca Bizjak 18, Isabelle Boccon-Gibod 19, Hanna Bonnekoh 20 21, Laurence Bouillet 19, Zenon Brzoza 22, Paula Busse 23, Regis A Campos 24 25, Emily Carne 26, Niall Conlon 27, Roberta F Criado 28, Eduardo M de Souza Lima 29, Semra Demir 30, Joachim Dissemond 31, Sibel Doğan Günaydın 32, Irina Dorofeeva 33, Luis Felipe Ensina 34, Ragıp Ertaş 35, Silvia Mariel Ferrucci 36, Ignasi Figueras-Nart 37, Daria Fomina 38 39, Sylvie M Franken 40, Atsushi Fukunaga 41, Ana M Giménez-Arnau 42, Kiran Godse 43, Margarida Gonçalo 44, Maia Gotua 45, Clive Grattan 46, Carole Guillet 47, Naoko Inomata 48, Thilo Jakob 49, Gul Karakaya 50, Alicja Kasperska-Zając 51, Constance H Katelaris 52, Mitja Košnik 18, Dorota Krasowska 53, Kanokvalai Kulthanan 54, M Sendhil Kumaran 55, Claudia Lang 47, José Ignacio Larco-Sousa 56, Elisavet Lazaridou 57, Tabi Anika Leslie 58, Undine Lippert 59, Oscar Calderón Llosa 60, Michael Makris 61, Alexander Marsland 62, Iris V Medina 63, Raisa Meshkova 64, Esther Bastos Palitot 65, Claudio A S Parisi 66, Julia Pickert 67, German D Ramon 68, Mónica Rodríguez-Gonzalez 69, Nelson Rosario 70, Michael Rudenko 71, Krzysztof Rutkowski 72, Jorge Sánchez 73, Sibylle Schliemann 74, Bulent Enis Sekerel 75, Faradiba S Serpa 76, Esther Serra-Baldrich 77, Zhiqiang Song 78, Angèle Soria 79, Maria Staevska 80, Petra Staubach 81, Anna Tagka 82, Shunsuke Takahagi 83, Simon Francis Thomsen 84, Regina Treudler 85, Zahava Vadasz 86, Solange Oliveira Rodrigues Valle 87, Martijn B A Van Doorn 88, Christian Vestergaard 89, Nicola Wagner 90, Dahu Wang 91, Liangchun Wang 92, Bettina Wedi 93, Paraskevi Xepapadaki 94, Esra Yücel 95, Anna Zalewska-Janowska 96, Zuotao Zhao 97, Torsten Zuberbier 21, Marcus Maurer 98

Show All

Affiliations

expand

Affiliations

1Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey.
2Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey.
3Urticaria Center of Reference and Excellence (UCARE), School of Medicine, Universidad de Especialidades Espíritu Santo, Samborondón, Ecuador and RespiraLab, Research, Guayaquil, Ecuador.
4Urticaria Center of Reference and Excellence (UCARE), Faculdade de Medicina do ABC, Santo André, Brazil.
5Alergoskin Alergia e Dermatologia SS ltda, Santo André, Brazil.
6UCARE Center, São Paulo, Brazil.
7Urticaria Center of Reference and Excellence (UCARE), Division of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, 7925, South Africa.
8Urticaria Center of Reference and Excellence (UCARE), Cleveland Clinic Abu Dhabi, UAE.
9Urticaria Center of Reference and Excellence (UCARE), University of São Paulo, São Paulo, Brazil.
10Urticaria Center of Reference and Excellence (UCARE), Microbiology Department, Faculty of Medicine, Kuwait University, Safat, Kuwait.
11Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
12Urticaria Center of Reference and Excellence (UCARE), King Faisal Specialist Hospital & Research Center, Al Faisal University, Riyadh, Saudi Arabia.
13Urticaria Center of Reference and Excellence (UCARE), Preto Medical School, University of São Paulo, São Paulo, Brazil.
14Urticaria Center of Reference and Excellence (UCARE), Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.
15Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
16Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, Immunology and Dermatology, Department of Pediatrics, McGill University Health Center, Montreal, QC, Canada.
17Urticaria Center of Reference and Excellence (UCARE), University of Cincinnati College of Medicine, Division of Immunology, Rheumatology and Allergy, Cincinnati, USA.
18Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
19Urticaria Center of Reference and Excellence (UCARE), Clinical Immunology/Internal Medicine Department, National Reference Center for Angioedema, Grenoble University Hospital, Grenoble, France.
20Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
21Autoinflammation Reference Center Charité (ARC2), Charité - Universitätsmedizin Berlin, Berlin, Germany.
22Urticaria Center of Reference and Excellence (UCARE), Department of Internal Medicine with Division of Allergology, Institute of Medical Sciences, University of Opole, Opole, Poland.
23Urticaria Center of Reference and Excellence (UCARE), Division of Clinical Immunology and Allergy, Icahn School at Mount Sinai, New York, NY, USA.
24Urticaria Center of Reference and Excellence (UCARE), Universidade Federal da Bahia, Salvador, Brazil.
25Serviço de Imunologia, Hospital das Clínicas Professor Edgard Santos, Salvador, Brazil.
26Urticaria Center of Reference and Excellence (UCARE), University Hospital of Wales, Cardiff, UK.
27Urticaria Center of Reference and Excellence (UCARE), Department of Immunology, St James's Hospital and Trinity College, Dublin, Ireland.
28Urticaria Center of Reference and Excellence (UCARE), Faculdade de Medicina do ABC (FMABC), Santo André, Brazil.
29Urticaria Center of Reference and Excellence, (UCARE), Faculdade de Ciências, Médicas e da Saúde de Juiz de Fora (SUPREMA), Hospital Maternidade Therezinha de Jesus, Minas Gerais, Brazil.
30Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
31Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Venereology and Allergology, University of Essen, Essen, Germany.
32Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
33Urticaria Center of Reference and Excellence (UCARE), Department of Allergy and Immunotherapy, Institute of Immunology, FMBA of Russia, Moscow, Russia.
34Urticaria Center of Reference and Excellence (UCARE), Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
35Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey.
36Urticaria Center of Reference and Excellence (UCARE), Ambulatorio di Dermatologia Allergologica e Professionale, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
37Urticaria Center of Reference and Excellence (UCARE), The Dermatology Department of the Hospital de Bellvitge, Universitat de Barcelona, Barcelona, Spain.
38Urticaria Center of Reference and Excellence (UCARE), Center of Allergy and Immunology, Moscow Ministry of Healthcare, Moscow, Russia.
39Department of Allergology and Clinical Immunology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
40Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands.
41Urticaria Center of Reference and Excellence (UCARE), Division of Dermatology, Kobe University, Graduate School of Medicine, Kobe, Japan.
42Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.
43Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, D Y. Patil University School of Medicine, Mumbai, India.
44Urticaria Center of Reference and Excellence (UCARE), Centro Hospitalar Universitário Coimbra and Faculty of Medicine, University of Coimbra, Clinica de Dermatologia, Coimbra, Portugal.
45Urticaria Center of Reference and Excellence (UCARE, Center of Allergy and Immunology, Tbilsi, Georgia.
46Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Guys & St Thomas' Hospital, London, UK.
47Urticaria Center of Reference and Excellence (UCARE), Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
48Urticaria Center of Reference and Excellence (UCARE), Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
49Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Allergy, University Medical Center Giessen (UKGM, Justus-Liebig-University Giessen, Giessen, Germany.
50Urticaria Center of Reference and Excellence (UCARE), School of Medicine, Department of Chest Diseases, Adult Allergy Unit, Hacettepe University, Sihhiye Ankara, Turkey.
51Urticaria Center of Reference and Excellence (UCARE), European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Zabrze, Poland.
52Urticaria Center of Reference and Excellence (UCARE), Immunology & Allergy Unit, Department of Medicine, Campbelltown Hospital, Campbelltown, NSW, Australia.
53Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
54Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
55Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
56Urticaria Center of Reference and Excellence (UCARE), Clinica San Felipe, Lima, Peru.
57Urticaria Center of Reference and Excellence (UCARE), Second department of Dermatology and Venereology, Aristotle University of Thessaloniki, General Hospital Papageorgiou, Thessaloniki, Greece.
58Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Royal Free Hospital, London, UK.
59Urticaria Center of Reference and Excellence (UCARE, Department of Dermatology, Medical Center of University Goettingen, Venerology und Allergology, Goettingen, Germany.
60Urticaria Center of Reference and Excellence (UCARE), Department of Allergy, SANNA el Golf, San Isidro, Lima.
61Urticaria Center of Reference and Excellence (UCARE), Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital "Attikon", Athens, Greece.
62Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, The Urticaria Clinic, Salford Royal Foundation Trust, University of Manchester, Manchester, UK.
63Urticaria Center of Reference and Excellence (UCARE), Allergy and Clinical Immunology Department, Centro Médico Vitae, de Julio, Argentina.
64Urticaria Center of Reference and Excellence (UCARE), Department of Clinical Immunology and Allergology, Smolensk State Medical University, Smolensk, Russia.
65Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Hospital Universitário Lauro Wanderley, João Pessoa, PB, Brazil.
66Urticaria Center of Reference and Excellence (UCARE), Adults and Pediatrics Allergy Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
67Urticaria Center of Reference and Excellence (UCARE), Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany.
68Urticaria Center of Reference and Excellence (UCARE), Instituto de Alergia e Inmunologia del Sur, Buenos Aires, Argentina.
69Urticaria Center of Reference and Excellence (UCARE), Department of Allergy, Hospital Español de México, Mexico City, Mexico.
70Urticaria Center of Reference and Excellence (UCARE), Federal University of Parana, Rua General Carneiro, Curitiba, Brazil.
71Urticaria Center of Reference and Excellence (UCARE), London Allergy and Immunology Centre, London, UK.
72Urticaria Center of Reference and Excellence (UCARE), Department of Allergy, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
73Urticaria Center of Reference and Excellence (UCARE), Department of Pediatrics, Graduate Program on Allergology, University of Antioquia, Medellín, Colombia.
74Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, University Hospital Jena, Germany.
75Urticaria Center of Reference and Excellence (UCARE), Department of Pediatric Allergy, Hacettepe University Faculty of Medicine, Ankara, Turkey.
76Urticaria Center of Reference and Excellence (UCARE), Hospital Santa Casa de Misericórdia de Vitória, Espírito Santo, Brazil.
77Urticaria Center of Reference and Excellence (UCARE), Dermatology Department, Hospital Sant Pau, Barcelona, Spain.
78Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China.
79Urticaria Center of Reference and Excellence (UCARE), Service de Dermatologie et Allergologie, Hopital Tenon, APHP, Université, Paris, Sorbonne, France.
80Urticaria Center of Reference and Excellence (UCARE), Department of Allergy, Sofia Medical University, Sofia, Bulgaria.
81Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, University Medical Center, Mainz, Germany.
82Urticaria Center of Reference and Excellence (UCARE), First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "A. Syggros" Hospital, Referral Center of Occupational Dermatological Diseases, Athens, Greece.
83Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
84Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
85Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Venerology and Allergology and Leipzig Interdisciplinary Center of Allergology Comprehensive Allergy Center, UMC Leipzig, Leipzig, Germany.
86Urticaria Center of Reference and Excellence (UCARE), Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel.
87Urticaria Center of Reference and Excellence (UCARE), Federal University of Rio de Janeiro, Department of Internal Medicine, Immunology Service, Rio de Janeiro, Brazil.
88Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
89Urticaria Center of Reference and Excellence (UCARE), Aarhus University Hospital, Aarhus, Denmark.
90Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology, University of Erlangen, Erlangen, Germany.
91Urticaria Center of Reference and Excellence (UCARE), Dermatovenerological Department, The Second Hospital of HeBei Medical University, Shijiazhuang, HeBei Province, China.
92Urticaria Center of Reference and Excellence (UCARE, Dermatology Department of Sun Yat-sen Memorial Hospital, Guangzhou, China.
93Urticaria Center of Reference and Excellence (UCARE, Department of Dermatology and Allergology, Hannover Medical School, Allergology Division, Hannover, Germany.
94Urticaria Center of Reference and Excellence (UCARE), Department of Allergy, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
95Urticaria Center of Reference and Excellence (UCARE), Department of Pediatric Allergy and Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
96Urticaria Center of Reference and Excellence (UCARE), Chair of Clinical Immunology and Rheumatology, Department of Psychodermatology, Medical University of Lodz, Lodz, Poland.
97Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venerology, Peking University First Hospital, Beijing Key Laboratory of molecular Diagnosis on Dermatoses and National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
98Urticaria Center of Reference and Excellence (UCARE), Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.

01 March 2021

doi: 10.1111/all.14687

Abstract

Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown.

Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19.

Materials and methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences.

Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19.

Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.

Keywords: COVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatment.

References

1. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy 2020;75(2):423-432. https://doi.org/10.1111/all.14037
1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73(7):1393-1414. https://doi.org/10.1111/all.13397
1. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, Guillén-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis. Br J Dermatol. 2016;175:1153-1165.
1. Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study. J Dermatol Sci. 2017;87(1):60-69. https://doi.org/10.1016/j.jdermsci.2017.02.283
1. Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy 2020;50(10):1166-1175. [published online ahead of print, 2020 Jul 31]. Clin Exp Allergy. 2020;10.1111/cea.13716. doi:10.1111/cea.13716.
1. The COVID-19 Testing Insights Initiative. Coronavirus Resource Center of the John Hopkins University. Available from: https://coronavirus.jhu.edu/. Retrieved September 20, 2020.
1. Criado PR, Abdalla BMZ, de Assis IC, et al. Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflamm Res. 2020;69(8):745-756.
1. Maurer M, Metz M, Bindslev-Jensen C, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy 2016;71(8):1210-1218. https://doi.org/10.1111/all.12901
1. American Academy of Dermatology. Guidance on the use of immunosuppressive agents. https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics. Retrieved on 30 September 2020.
1. Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy 2020;75(11):2764-2774.
1. Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020;4:53-68.
1. Kempuraj D, Selvakumar GP, Ahmed ME, et al. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation [published online ahead of print, 2020 Jul 18]. Neuroscientist. 2020;1073858420941476. doi:10.1177/1073858420941476.
1. Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents 2020;34(1):9-14.
1. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 2020;75:1564-1581. https://doi.org/10.1111/all.14364
1. Criado PR, Pagliari C, Criado RFJ, Marques GF, Belda W Jr. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;25:e14068.
1. Rodriguez L, Pekkarinen PT, Lakshmikanth T, et al. Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Cell Rep Med. 2020;1(5):100078.
1. Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of cutaneous manifestations of COVID-19: a rapid retrospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77.
1. Criado PR, Criado RFJ, Pincelli TP, Yoshimoto TA, Naufal GGA, Abdalla BMZ. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. Int J Dermatol. 2020;59(10):1294-1295.
1. World Health Organization. COVID-19 therapeutic trial synopsis. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Trea.... Retrieved on 30th September 2020.
1. Portnoy J, Waller M, Elliott T. Telemedicine in the Era of COVID-19. J Allergy Clin Immunol Pract. 2020;8(5):1489-1491. https://doi.org/10.1016/j.jaip.2020.03.008
1. Smith AC, Thomas E, Snoswell CL, et al. Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare. 2020;26(5):309-313.
1. Aldunate R, Nussbaum M. Teacher adoption of technology. Comput Hum Behav. 2013;29(3):519-524.
1. Ashfaq A, Memon SF, Zehra A, et al. Knowledge and attitude regarding telemedicine among doctors in Karachi. Cureus. 2020;12(2):e6927. https://doi.org/10.7759/cureus.6927
1. Maurer M, Weller K, Magerl M, et al. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organ J. 2020;13(11):100475.
1. Calderón J, Cherrez A, Ramón GD, et al. Information and communication technology use in asthmatic patients: a cross-sectional study in Latin America. ERJ Open Res. 2017;3(3):00005-2017. https://doi.org/10.1183/23120541.00005-2017
1. Statista. Most popular global mobile messenger apps as of based on number of monthly active users. 2020. Available from: https://www.statista.com/statistics/258749/most-popular-global-mobile-me... Retrieved September 20, 2020.
1. Salman A, Alper S, Atakan N, et al. Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 Pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Turkderm-Turk Arch Dermatol Venereology 2020;54:71-75.
1. Valent P, Akin C, Bonadonna P, et al. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol. 2020;146(2):300-306. https://doi.org/10.1016/j.jaci.2020.06.009
1. Hogan RB II, Hogan Iii RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020;63:101942. 10.1016/j.pupt.2020.101942.
1. Zhao T, Ji CM, Yu MJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750.
1. Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on Rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med 2017;196(8):985-992.
1. Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735-1743.
1. Ghazawi FM, Lim M, Dutz JP, Kirchhof MG. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: An evidence-based recalibration. Int J Dermatol. 2020;59(9):1043-1056.
1. Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82(5):e173-e175.
1. Ozturk AB, Baççıoğlu A, Soyer O, Civelek E, Şekerel BE, Bavbek S. Change in allergy practice during the COVID-19 pandemic. Int Arch Allergy Immunol. 2020;15:1-4.
1. Mehta B, Jannat-Khah D, Mancuso CA, et al. Geographical variations in COVID-19 perceptions and patient management: A national survey of rheumatologists. Semin Arthritis Rheum. 2020;50(5):1049-1054. https://doi.org/10.1016/j.semarthrit.2020.06.017
1. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19). China. China CDC Weekly. 2020;2(8):113-122.
1. Algaadi SA. Urticaria and COVID-19: A review. Dermatol Ther. 2020;9:e14290.
1. Imbalzano E, Casciaro M, Quartuccio S, et al. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc. 2016;37(1):18-22.
1. Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020;8(277):55-64.
1. Mazza MG, De Lorenzo R, Conte C, et al. COVID-19 BioB Outpatient Clinic Study group, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020:S0889-1591(20)31606-31608.
1. Varghese R, Rajappa M, Chandrashekar L, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria. Ann Allergy Asthma Immunol. 2016;116(4):344-348.e1. https://doi.org/10.1016/j.anai.2016.01.016. Epub 2016 Feb 20
1. Dyke SM, Carey BS, Kaminski ER. Effect of stress on basophil function in chronic idiopathic urticaria. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2008;38:86-89.
1. Basak PY, Erturan I, Yuksel O, Kazanoglu OO, Vural H. Evaluation of serum neuropeptide levels in patients with chronic urticaria. Indian J Dermatol Venereol Leprol. 2014;80(5):483.
1. Rössing K, Novak N, Mommert S, et al. Brain-derived neurotrophic factor is increased in serum and skin levels of patients with chronic spontaneous urticaria. Clin Exp Allergy. 2011;41(10):1392-1399.

Show All

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Affiliations

Abstract

References

Page Navigation